Navigation Links
Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
Date:10/20/2008

EAST SETAUKET, N.Y., Oct. 20 /PRNewswire-FirstCall/ -- John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT), announces the appointment of Mel Sorensen, M.D. to the company's Board of Directors.

Dr. Sorensen is currently Board Director, President and Chief Executive Officer of Ascenta Therapeutics. He is a highly experienced leader and administrator in cancer therapeutics and cancer drug development.

Trained as a medical oncologist, Dr. Sorensen has dedicated his career to clinical cancer research and cancer drug development. After completing his oncology fellowship at the Mayo Clinic, Rochester, MN in 1988, Dr. Sorensen spent seven years at the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP). At CTEP, he managed collaborations between companies developing new anti-cancer agents and academic clinics and clinical cooperative groups. He had responsibility for over 40 research compounds.

Following NCI, Dr. Sorensen spent nearly eight years at large pharmaceutical companies in leadership roles in oncology clinical development and medical affairs. He established Bayer's first clinical oncology department and oversaw multiple clinical trials (Phase 1, 2 and 3) of novel agents. He subsequently joined GlaxoSmithKline (GSK) as Vice-President, Global Leader and North American Head of Clinical Development and Medical Affairs for Oncology, where he recruited a large team of physicians and scientists and led global clinical development of chemotherapeutic agents. While at GSK and Bayer, he was very active in business development, facilitating several in-licensing agreements and joint collaborations (including Onyx, SB, Corixa, Nippon Kayaku, and Hoffmann-La Roche).

Dr. Sorensen joined Ascenta Therapeutics in August 2004. Under his leadership, in less than three years Ascenta was transformed from a 5-person start-up with a single preclinical program int
'/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
2. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
3. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
4. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
5. SourceSolution Announces the Launch of Its Initiative to Simplify Outsourcing Decisions for Biotechnology and Pharmaceutical Companies
6. Vineland Welcomes Dr. Daryl Somers as Research Chair, Molecular Breeding and Biotechnology
7. BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World
8. Monsanto Recognized as Top Biotechnology Employer by Science Magazine
9. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
10. Jacobs Receives Contract From Gedeon Richter for New Biotechnology Facility in Hungary
11. InNexus Biotechnology CEO to Present at BioContactQuebec 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ployment grew by 29,000 jobs in October, and the ...th during the U.S. recession. However, clinics and... systems are coming closer to having to actually c...rs. , (Vocus) November 24... in October despite the shedding of jobs in most o...
(Date:11/24/2009)...RNewswire-Asia/ -- Shanghai Biolaxy announced the,...) has approved the,investigational new drug applic... an innovative insulin formulation to treat diabet...ts first phase I clinical study. , Diabet...ose and poor,metabolism. The complications of diab...
(Date:11/24/2009)...NTO, Nov. 24 /PRNewswire-FirstCall/ - Hamilton Tho...c., a leading provider of advanced laser systems a...ility clinic markets, today reported operational a...eptember 30, 2009. , , Q3 2009 Highlights, ... million in Q3 2008, - Gross profit margin wa...
(Date:11/24/2009)... 24 Health Robotics today announce...with a group of selected,investors. This recently ...e,name Health Robotics Canada, Inc. and will marke... of the Future concept, which includes the,revolut...(TM), and OMM(TM).,Health Robotics Canada Inc. wil...
Breaking Biology Technology:The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Biolaxy Secures IND Approval for Oral Insulin 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Hamilton Thorne announces third quarter results 8Hamilton Thorne announces third quarter results 9Hamilton Thorne announces third quarter results 10Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 3
...e III von Willebrand Disease, a serious, hereditar...gion, KING OF PRUSSIA, Pa., Dec. 19 CSL Behring ... Medical Education (MOHME) has,granted rights to t...ive,basis throughout Iran, beginning immediately. ...llebrand Disease, a serious, hereditary, and,somet...
... Protocol Assessment for Reviroc, AMSTERDAM, Dece... successfully completed an End of Phase II meeting...ation (FDA). Reviroc is under,development for elim...n,bone marrow transplantations for end-stage blood...m the completed phase II clinical Reviroc trial is...
...ients the chance to live twice as long without the...ASEL, Switzerland, Dec. 19 Avastin (bevacizumab),...today in Europe for the,first-line treatment of pa...mbination with interferon (IFN), the current stand...arcinoma (RCC) is a disease that kills over,100,00...
Other Biology Technology:CSL Behring Expands Into Middle East Market with Haemate(R) P 2CSL Behring Expands Into Middle East Market with Haemate(R) P 3Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc 2Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer 2Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer 3
(Date:11/24/2009)...itutes fish food is a matter of debate. A high-pro... almost 50 percent of their carbon from trees and ... terrestrial and aquatic ecosystems. , But new r...is is not likely to be true. Algae provide a much ...ding to research published this week in the Proce...
(Date:11/23/2009)...ge, Mass. November 23, 2009 Applied mathematicia... Hosta lancifolia ), a characteristic long leaf wi... ripples along the edges. The simple cause of the ...from bending during differential growthwas reveale... foam ribbons. , Haiyi Liang, a postdoctoral stu...
(Date:11/23/2009)..., Ill. A new study provides "incontrovertible evi... the island of Sumatra about 73,000 years ago defo...m the epicenter, researchers report. , The volca...h into the atmosphere, leaving a crater (now the w...rs long and 35 kilometers wide. Ash from the event...
Breaking Biology News(10 mins):Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3The cause behind the characteristic shape of a long leaf revealed 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Applied Medical Selected by the Premier Healthcare Alliance to Highlight Commitment to Healthcare Quality Improvement Innovation 49163 1Applied Medical Selected by the Premier Healthcare Alliance to Highlight Commitment to Healthcare Quality Improvement Innovation 49163 2Applied Medical Selected by the Premier Healthcare Alliance to Highlight Commitment to Healthcare Quality Improvement Innovation 49163 3Digital Mammography and Clinical Review Display Units Energising the European Markets for Medical Imaging Display Monitors Finds Frost 26 Sullivan 49162 1Digital Mammography and Clinical Review Display Units Energising the European Markets for Medical Imaging Display Monitors Finds Frost 26 Sullivan 49162 2Digital Mammography and Clinical Review Display Units Energising the European Markets for Medical Imaging Display Monitors Finds Frost 26 Sullivan 49162 3Digital Mammography and Clinical Review Display Units Energising the European Markets for Medical Imaging Display Monitors Finds Frost 26 Sullivan 49162 4STAAR Surgical Completes Common Stock Offering 49160 1STAAR Surgical Completes Common Stock Offering 49160 2STAAR Surgical Completes Common Stock Offering 49160 3
...NDO, Fla., Aug. 18 Central Florida based locksmit... announced its strategic,alliance with security fi...tely, all product and service lines, as well as al...uellar,s in conjunction with Absolute. The,change ...tion just blocks,away from the previous headquarte...
... COLUMBIA, Mo. Recently, Harvard researchers repo...f genetic defects, making it nearly impossible to ...rder. Now, University of Missouri researchers are ... facial features and brain structures of children ...able them to develop a formula for earlier detecti...
...he Woods Institute for the Environment has awarded... research programs at Stanford that help solve the... water is crucial to human survival and well-being... have no access to safe water supplies, and more t...aid Woods Institute Senior Fellow Richard Luthy, a...
Other Biology News:Cuellar's Safe and Lock Announces Strategic Alliance with Absolute Access and Security 2Researchers study facial structures, brain abnormalities to reveal formula for detection of autism 2New planning grants to fund research on freshwater issues 2New planning grants to fund research on freshwater issues 3
Polaroid Standard Electrophoresis Hood from Bio-Rad
...en tissue microarrays are derived from frozen embe...s quality control procedures to ensure the highest...bled in one block, sectioned at a thickness of 7 m...large (3-5 mm in diameter) in comparison to core s...
...en tissue microarrays are derived from Paraffin em...ous quality control procedures to ensure the highe...embled in one block, sectioned at a thickness of 5...e large (3-5 mm in diameter) in comparison to core...
...en tissue microarrays are derived from Paraffin em...ous quality control procedures to ensure the highe...embled in one block, sectioned at a thickness of 5...e large (3-5mm in diameter) in comparison to core ...
Biology Products: